|Event Name||2016 13th Global CardioVascular Clinical Trialists Forum
Thursday, December 01, 2016
Saturday, December 03, 2016
Embassy of France
District of Columbia
|Description||How should we interpret the results of the major recent trials? What is the impact on clinical practice?
How can we design and conduct better and cheaper trials that address true unmet needs?
How can we improve operating procedures and streamline trial execution?
How to operate within the regulatory environment? Foster cross-talk with regulatory agencies?
And more generally, how to create better and safer methods for treating cardiovascular disease?
The Global CardioVascular Clinical Trialists Forum (CVCT) is dedicated to the discussion of clinical trials in cardiovascular disease and aims to provide answers to these questions.
CVCT is a true Forum where scientific productivity and peer-to-peer exchange are at their best.
CVCT meetings are unique, bringing together a carefully selected faculty of opinion leaders, clinical trialists, investigators, regulators, statisticians, industry R&D experts, decision makers and practitioners. Over the years CVCT has attracted audience from over 30 different countries, with participants coming from Western and Eastern Europe, the USA, South America, Asia and Middle East.
The meeting encourages knowledge-sharing between participants as CVCT aims to familiarize practitioners and investigators with the science of clinical trials from protocol design to result interpretation. Further, CVCT Forum puts attendees into direct contact with primary investigators, senior trial scientists as well as research and development experts from pharmaceutical/device companies and experts from regulatory agencies.
Who should attend CVCT Forum?
• Engage with practitioners and other stakeholders on the relevance of ongoing research and future trials.
Pharmaceutical and device companies
• Present and discuss current research and future trials with scientific and regulatory professionals.
• Learn new approaches for managing safe and effective studies from worldwide colleagues in all trial-related fields.